{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:40:34Z","timestamp":1791265234157,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T00:00:00Z","timestamp":1451260800000},"content-version":"vor","delay-in-days":5474,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2001]]},"DOI":"10.1111\/j.1469-0691.2001.tb00012.x","type":"journal-article","created":{"date-parts":[[2006,9,22]],"date-time":"2006-09-22T15:14:50Z","timestamp":1158938090000},"page":"68-79","source":"Crossref","is-referenced-by-count":58,"special_numbering":"S2","title":["Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children"],"prefix":"10.1016","volume":"7","author":[{"given":"J.","family":"Tollemar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Klingspor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Ringd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib1","series-title":"Fungal Infection: Diagnosis and Management","author":"Richardson","year":"1993"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.7326\/0003-4819-61-2-334","article-title":"Amphotericin B toxicity. Combined clinical staff conference at the National Institutes of Health","volume":"61","author":"Utz","year":"1964","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/106002808001400303","article-title":"A review of complications of amphotericin-B therapy: recommendations for prevention and management","volume":"14","author":"Maddux","year":"1980","journal-title":"Drug Intelligence Clin Pharmacy"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib4","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1056\/NEJM198112033052306","article-title":"Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury","volume":"305","author":"Shulman","year":"1981","journal-title":"New Engl J Med"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jac\/8.5.371","article-title":"Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes","volume":"8","author":"New","year":"1981","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1164\/arrd.1982.125.5.610","article-title":"Amphotericin B in liposomes: a novel therapy for histoplasmosis","volume":"125","author":"Taylor","year":"1982","journal-title":"Am Rev Respir Dis"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib7","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/infdis\/145.2.748","article-title":"Treatment of murine cryptococcosis with liposome-associated amphotericin B","volume":"145","author":"Graybill","year":"1982","journal-title":"J Infectious Dis"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/cdd.1983.1.37","article-title":"Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis","volume":"1","author":"Lopez-Berestein","year":"1983","journal-title":"Cancer Drug Delivery"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib9","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/infdis\/151.4.704","article-title":"Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminar study","volume":"151","author":"Lopez-Berestein","year":"1985","journal-title":"J Infectious Dis"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib10","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1001\/archinte.1989.00390110097022","article-title":"Treatment of systemic fungal infections with liposomal amphotericin B","volume":"149","author":"Lopez-Berestein","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1399-0012.1990.tb00047.x","article-title":"Liposomal Amphotericin-B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation","volume":"4","author":"Tollemar","year":"1990","journal-title":"Clin Transplant"},{"issue":"4","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-199223040-00004","article-title":"Liposomal and lipid formulations of amphotericin B","volume":"23","author":"Janknegt","year":"1992","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl. 5","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib13","first-page":"S8","article-title":"Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations","volume":"14","author":"Heinemann","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib14","first-page":"1","article-title":"Mechanism of the selective toxicity of amphotericin B incorporated into liposomes","volume":"31","author":"Juliano","year":"1987","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib15","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/infdis\/155.4.766","article-title":"Pharmacokinetics of amphotericin B in infants and children","volume":"155","author":"Starke","year":"1987","journal-title":"J Infect Dis"},{"issue":"Suppl. B","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/28.suppl_B.83","article-title":"Liposomal amphotericin B (AmBisome): safety data from a phase II\/III clinical trial","volume":"28","author":"Meunier","year":"1991","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. B","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/28.suppl_B.73","article-title":"Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients","volume":"28","author":"Ringd\u00e9n","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib18","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0140-6736(92)91698-8","article-title":"Liposomal amphotericin B","volume":"339","author":"Ringd\u00e9n","year":"1992","journal-title":"Lancet"},{"issue":"Suppl. 4D","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib19","first-page":"34","article-title":"Candidiasis in the transplant patient","volume":"77","author":"Clift","year":"1984","journal-title":"Am J Med"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib20","first-page":"635","article-title":"Variables predicting deep fungal infections in bone marrow transplant recipients","volume":"4","author":"Tollemar","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1439-0507.1992.tb00850.x","article-title":"A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients","volume":"35","author":"Tollemar","year":"1992","journal-title":"Mycoses"},{"issue":"Suppl. 5","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib22","first-page":"S10","article-title":"Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin","volume":"14","author":"Ringd\u00e9n","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib23","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S0140-6736(94)90663-7","article-title":"Allergic reactions and other rare side-effects of liposomal amphotericin. (Letter)","volume":"344","author":"Ringd\u00e9n","year":"1994","journal-title":"Lancet"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1439-0507.1996.tb00123.x","article-title":"Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients \u2013 improvements gained","volume":"39","author":"Ekel\u00f6f Andstr\u00f6m","year":"1996","journal-title":"Mycoses"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM198603203141201","article-title":"Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia","volume":"314","author":"Storb","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib26","first-page":"221","article-title":"Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients","volume":"7","author":"Ringd\u00e9n","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib27","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00007890-199410270-00005","article-title":"Long-term follow-up of a randomized trial comparing T-cell-depletion with a combination of methotrexate and cyclosporin in adult leukemic marrow transplant recipients","volume":"58","author":"Ringd\u00e9n","year":"1994","journal-title":"Transplantation"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib28","first-page":"577","article-title":"A randomized double-blind study of AmBisome (liposomal amphotericin B) prophylaxis of invasive fungal infections in bone marrow transplant recipients","volume":"12","author":"Tollemar","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib29","series-title":"Diagnosis and Therapy of Systemic Fungal Infections","first-page":"71","author":"Shah","year":"1989"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib30","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1399-0012.1991.tb00103.x","article-title":"Invasive Candida albicans infections in orthotopic liver graft recipients. Incidence and risk factors","volume":"5","author":"Tollemar","year":"1991","journal-title":"Clin Transplant"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00007890-199501150-00009","article-title":"Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study","volume":"59","author":"Tollemar","year":"1995","journal-title":"Transplantation"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib32","first-page":"1195","article-title":"Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infection in liver transplant recipients: Long-term results of a randomized, placebo-controlled trial","volume":"27","author":"Tollemar","year":"1995","journal-title":"Transplant Proc"},{"issue":"4","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00002018-199513040-00001","article-title":"Lipid formulations of Amphotericin B. Less toxicity but at what economic cost?","volume":"13","author":"Tollemar","year":"1995","journal-title":"Drug Safety"},{"issue":"4","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib34","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/00003495-199855040-00008","article-title":"Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis","volume":"55","author":"Coukell","year":"1998","journal-title":"Drugs"},{"issue":"12","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib35","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00002030-199712000-00010","article-title":"Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis","volume":"11","author":"Leenders","year":"1997","journal-title":"AIDS"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib37","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirial therapy in patients with persistent fever and neutropenia","volume":"340","author":"Walsh","year":"1999","journal-title":"New Engl J Med"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","article-title":"Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspted neutropenia-associated invasive fungal infections","volume":"103","author":"Leenders","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib39","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1086\/515033","article-title":"An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin b for treatment of invasive aspergillosis","volume":"27","author":"Ellis","year":"1998","journal-title":"Clin Infectious Dis"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib40","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infectious Dis"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib41","unstructured":"Ringd\u00e9n O, Ekel\u00f6f Andstr\u00f6m E et al. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone marrow transplantation. 1997; 1 (2): 124\u20139."},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/08880019209018337","article-title":"Conventional versus liposomal amphotericin B in immunosuppressed children","volume":"9","author":"Zoubek","year":"1992","journal-title":"Pediatr Hematol Oncol"},{"issue":"2","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib43","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1542\/peds.89.6.1259","article-title":"Liposomal amphotericin B (AmBisome) for treatment of disseminated fungal infections in tw infants of very low birth weight","volume":"89","author":"Lackner","year":"1992","journal-title":"Pediatrics"},{"issue":"5","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib44","first-page":"376","article-title":"Liposomal amphotericin B (AmBisome) in neutropenic children with hematological malignancies and systemec fungal infections (Abstract)","volume":"20","author":"Nowoczyn","year":"1992","journal-title":"Med Pediatr Oncol"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF01695916","article-title":"Tolerance of high doses of amphotericin B by infusion of a liposomal formulation in children with cancer","volume":"68","author":"Emminger","year":"1994","journal-title":"Ann Hematol"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib46","first-page":"175","article-title":"High cure rate of invasive fungal infections in immunocompromised children using AmBisome","volume":"26","author":"Ringd\u00e9n","year":"1994","journal-title":"Transplant Proc"},{"issue":"1","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00043426-199602000-00018","article-title":"Opportunistic osteomyelitis in the jaws of children on immunosuppressive chemotherapy","volume":"18","author":"Hovi","year":"1995","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib48","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/sj.bmt.1700821","article-title":"Liposomal amphotericin B (AmBisome) is safe in bone marrow transplantation for primary immunodeficiency","volume":"19","author":"Pasic","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF02768745","article-title":"Candida infection in very low birth-weight infants: Outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome)","volume":"26","author":"Weitkamp","year":"1997","journal-title":"Infection"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3476(97)70165-3","article-title":"Treatment of visceral leishmaniasis in children with liposomal amphotericin B","volume":"131","author":"DiMartino","year":"1997","journal-title":"J Pediatr"},{"issue":"1","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1128\/JCM.37.1.18-25.1999","article-title":"Disseminated infection due to Chrysosporium zonatum in a patient with chronic granulomatous disease and review of non-Aspergillus fungal infections in patients with this disease","volume":"37","author":"Roilides","year":"1999","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib52","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2165\/00019053-199202060-00008","article-title":"Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses","volume":"2","author":"Petsson","year":"1992","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1111\/j.1469-0691.2001.tb00012.x_bib53","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1200\/JCO.2000.18.12.2476","article-title":"Pharmacoeconomic analysis of liposomal amphotericin B versus c onventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients","volume":"18","author":"Cagnoni","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib51a","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00006454-199802000-00013","article-title":"Liposomal amphotericin B treatment for neonatal fungal infections","volume":"17","author":"Scarcella","year":"1998","journal-title":"Pediatr Infectious Dis J"},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib54a","unstructured":"Boogaerts MA. Pharmacoeconomic evaluation of AmBisome in febrile neutropenia. Abstract at 9th International Symposium on Infections in the Immunocompromised Host, Assisi, June 1996."},{"key":"10.1111\/j.1469-0691.2001.tb00012.x_bib56a","unstructured":"Greenberg RN, Cagnoni PJ, Prendergast MM et al. Abstract. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 17\u201320 September 2000."}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15301026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15301026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T23:39:38Z","timestamp":1736552378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X15301026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001]]},"references-count":56,"alternative-id":["S1198743X15301026"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2001.tb00012.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2001]]}}}